	US 11,697,801 B2
	AAV-mediated delivery of therapeutic antibodies to the inner ear
Emmanuel John Simons, Brookline, MA (US); Robert Ng, Newton, MA (US); and Michael McKenna, Boston, MA (US)
Assigned to Akouos, Inc., Boston, MA (US)
Filed by Akouos, Inc., Boston, MA (US)
Filed on Aug. 3, 2021, as Appl. No. 17/392,910.
Application 17/392,910 is a continuation of application No. 16/955,715, previously published as PCT/US2018/066512, filed on Dec. 19, 2018.
Claims priority of provisional application 62/607,665, filed on Dec. 19, 2017.
Prior Publication US 2021/0363499 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 7/00 (2006.01); C07K 16/22 (2006.01); A61K 9/00 (2006.01); A61K 48/00 (2006.01); A61P 27/16 (2006.01)

CPC C12N 7/00 (2013.01) [A61K 9/0046 (2013.01); A61K 48/005 (2013.01); A61P 27/16 (2018.01); C07K 16/22 (2013.01); C12N 2750/14143 (2013.01)]

25 Claims

1. An adeno-associated virus (AAV) vector comprising a nucleotide sequence which comprises:

(i) a first coding sequence that encodes a first polypeptide comprising an antibody heavy chain variable domain operably linked to a first signal peptide, and a second coding sequence that encodes a second polypeptide comprising an antibody light chain variable domain operably linked to a second signal peptide,

wherein the sequence encoding the antibody heavy chain variable domain consists of SEQ ID NO: 52, and the sequence encoding the antibody light chain variable domain consists of SEQ ID NO: 53, and

(ii) a sequence encoding a thosea asigna virus 2A (T2A) peptide that is present between the first coding sequence and the second coding sequence,

wherein the first and second polypeptides together specifically bind to one or more mammalian VEGF proteins.